Correction: Dual neutralisation of interleukin-17A and interleukin-17F with bimekizumab in patients with active ankylosing spondylitis: results from a 48-week phase llb, randomised, double blind, placebo-controlled, dose-ranging study
Open Access
- 11 October 2021
- journal article
- correction
- Published by BMJ in Annals Of The Rheumatic Diseases
- Vol. 80 (11), e186
- https://doi.org/10.1136/annrheumdis-2020-216980corr2
Abstract
No abstract availableThis publication has 1 reference indexed in Scilit: